Monoclonal antibodies obtained by Phage Display with FDA approval.
\r\n\tThe chapters of this book will contribute to the current knowledge or summarize available evidence related to the prevalence, diagnostic criteria and tools, laboratory investigations, the pathophysiology, underlying psychological mechanisms, physical and mental health consequences, therapy, rehabilitation and the social and economic burden of these disorders.
\r\n\r\n\tManuscripts on biological aspects such as genetics, epigenetics, the microbiome, endocrine and metabolic disturbances, inflammation, laboratory testing and imaging are just as welcome as contributions on the psychological mechanisms involved in the origin and maintenance of eating- and weight-related problems.
\r\n\r\n\tAs therapeutic approaches include diet, physical exercise, psychotherapy, nursing, family therapy, occupational and art therapy, drug treatment, bariatric surgery and brain stimulation, submissions from all these areas and disciplines are highly appreciated.
\r\n\t
When thinking about the development of virus detection and neutralization technologies whose bases of action are immunoglobulins, it is necessary to understand the structure of the viral particle of interest. In addition to the sequence of amino acid residues that make up the target epitopes, their position in the particle and their function in the process of infection and viral replication influence the design experiments aiming the obtantion of antibodies with a diagnostic and therapeutic potential.
\nThe structures of flavivirus have been determined and studied, mainly, by combining cryo-electron microscopy with data from X-ray diffraction experiments using crystallography of viral proteins in the presence or not of antibody molecules. Results of this combination showed that the flavivirus is composed of a dense icosahedral electron nucleus and a lipid bilayer surrounding it. The genome comprises a sequence of ~10,700 nucleotides of a positive-sense RNA that encodes a polyprotein that is cleaved in 3 structural proteins, capsid protein (C), membrane protein (M), and envelope protein (E), and in 7 nonstructural proteins, NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5 [1]. The NS1 protein plays a role in viral replication and is often shown to be a soluble antigen secreted into the bloodstream, interacting with components of the immune system. NS5 is the largest and most conserved nonstructural protein and acts in the transcription process of viral RNA [2, 3].
\nThe icosahedral capsid is small and poorly organized, but it provides enough space for the genome and is surrounded by the envelope, so there are few connections between these structures, unlike what is found in other viruses. The viral envelope consists of two internal and concentric layers of phospholipids and an outer protein shell formed by regions of protein M and ectodomains of glycoprotein E organized in dimers which present protein determinants for the binding of the virus to the host cell (hemagglutination). Protein E contains three domains: domain I (DI), which is related to cell tropism and envelope organization; domain II (DII), which comprises the dimerization region and the fusion peptide; and domain III (DIII) with the function of binding to cell receptors, in the initial stage of viral infection [4, 5].
\nThe fusion loop is a highly conserved region between dengue virus (DENV) serotypes and all flaviviruses, responsible for the late stage of infection, in which the virus interacts with the endosomal membrane, resulting in the release of the nucleocapsid in the cytoplasm. When the particle is in the lysosomal vesicle during the infection process, a structural reorganization of the viral envelope occurs; the fusion loop is exposed and inserted in the lysosomal membrane. After the formation of the fusion loop contact, protein E starts to organize itself into trimmers, resulting in the expansion of the viral particle and the approximation of the viral and lysosomal membranes, forming the fusion lipid pore that allows the release of the viral genome to the cytoplasm [3, 6, 7].
\nDENV serotypes show great heterogeneity in the structure of viral proteins. However, there is also antigenic similarity between DENV serotypes and, for some peptide sequences, between flaviviruses. Phylogeny studies of virus sequences, by estimating the antigenic distance between them, concluded that serotypes 1 and 3 are the most similar, serotype 2 was the second to diverge evolutionarily, and serotype 4 is the one that presents greater genetic difference. There is a 32% difference in the structure of protein E of the four DENV serotypes. Specific mutations in the genome result in the antigenic variability found in each serotype [7, 8, 9].
\nMuch of the genetic difference between flaviviruses is due to protein E, which can show up to 60% difference in its amino acid sequence. In the phylogenetic analysis of the viruses, the DENV serotypes are closer to the Zika virus (ZIKV), with approximately 45% difference, and have 50 and 60% dissimilarity with West Nile virus (WNV) and yellow fever virus (YFV), respectively. DENV and other flaviviruses vary dramatically in terms of the amino acid sequence of the glycosylation region and the content of glycans added to the surface of E and precursor membrane protein (prM). Many epitopes of protein E are unique to a DENV serotype [4, 9, 10, 11]. It can also be observed in ZIKV, which has the glycosylation site, in the DI of protein E, different in conformation and length of the loop that contains this glycosylation site. The carbohydrate associated with this residue can act as a virus binding site in host cells. Thus, differences in this region of glycosylation can influence cell tropism, infection, and pathogenesis of these viruses [12]. Another important characteristic of ZIKV is the insertion of an alanine residue in the carboxyl termination of DIII, which is associated with an increased stability of this virus [13].
\nThe hydrophobic sequence of the fusion loop appears to be the only epitope that is conserved among all flaviviruses; however, the degree of exposure in this region varies substantially among viruses [6]. Nonstructural proteins, NS1 and NS5, also present some epitopes conserved among the DENV serotypes and other members of the flavivirus genus, but their position also varies between viral strains. The relationships of antigenic similarity between flaviviruses generate immune responses that are configured as cross-reactions with protective or pathological characteristics [5, 14, 15].
\nImmunoglobulins, or antibodies, are glycoproteins, expressed on the surface of B cells or secreted, that act in the neutralization and elimination of pathogens [16]. Antibodies are relatively flexible “Y”-shaped molecules made up of two heavy chains and two light chains, joined by an extensive network of non-covalent interactions, stabilized by disulfide bonds. Both types of chains are composed of constant and variable domains. The constant regions determine the functional properties of the antibody, and the variable regions determine the antigen-binding site. The light chain consists of a variable portion (VL) and a constant portion (CL) that can have two types of domains, kappa (ƙ) or lambda (λ). The heavy chain consists of a variable portion (VH) and three or four constant portions, depending on the class of the antibody, which are CH1, CH2, CH3, and CH4. The type of heavy chain determines the class, or isotype, of antibody, such as IgA, IgG, IgD, IgE, and IgM [17].
\nThe antibody molecule can be subdivided into portions of the crystallizable fragment (Fc) and antigen-binding fragment (Fab) region. The Fc portion has the constant domains (CH2, CH3, CH4), and the Fab portion consists of the VH-CH1 and VL-CL domains. The Fab portion retains the ability to bind to the antigen, and the Fc portion acts to mediate the effector functions of antibodies [17].
\nThree segments containing variability can be identified in both the VH and VL domains. These segments are the hypervariable regions that determine antigen specificity and are more commonly called complementarity-determining regions (CDRs)—CDR1, CDR2, and CDR3. The combination of CDRs from a VH with CDRs from a VL forms the region of interaction with the epitope, called the paratope [17]. The variability of the antigen-binding regions is responsible for the ability of different antibodies to bind to many structurally diverse antigens [18]. Figure 1 represents the structure of an IgG immunoglobulin and its domains.
\nClassical structure of an antibody. Structure of a class G immunoglobulin, representing the two portions of the molecule: two Fabs that correspond to the antigen-binding fragment and an Fc that corresponds to the crystallizable fragment. A type G antibody consists of two heavy polypeptide chains, each containing a VH and three constant domains (CH1, CH2, and CH3), and two light chains, each containing a VL and a CL. CDRs are three regions of hypervariability present in each of the variable domains. In addition to the natural format of the antibody, it is possible to generate recombinant antibodies such as the single-chain variable fragment (scFvs).
In cognate antigen recognition, some naïve B cells can initiate somatic hypermutation, generating new variable domains, that can be selected based on their ability of antigen binding, usually with high affinity compared to germinal domains. After antigen recognition, naïve B cells differentiate into antibody-secreting plasma cells. These plasma cells secrete antibodies with high affinity and, can differentiate into memory B cells. Memory B cells are highly specialized cells for quickly recognizing the antigen in subsequent exposure, can persist for years, and provide long-term humoral protection for decades. These functional features of memory B cells are the basis of effective vaccines [19].
\nThe knowledge about the mechanisms of antibody production and clonal selection of B cells led to the development of innovative hybridoma technology in 1975 [20]. The technique is based on the fusion of B lymphocytes with myeloma cells giving rise to hybrid cells that produce monoclonal antibodies (MAbs) continuously in vitro [21]. Therefore, MAbs are monovalent antibodies, which bind to the same epitope and are produced from a single B lymphocyte clone.
\nMAbs interact with a single epitope allowing a specific reactivity and affinity for target antigens. This feature is a great advantage over polyclonal antibodies, which have different epitope specificities and affinities [22, 23]. For this reason, MAbs have a broad clinical applicability in therapy for various illness, including cancer, transplant rejection, and autoimmune, infectious, hematologic, and cardiovascular diseases. Moreover, MAbs can play a significant role in the diagnosis and as antibody-drug conjugate for drug delivery. Thus, MAbs are considered a powerful tool for a wide range of medical applications.
\nAntibodies that bind to different flaviviruses are able to promote both the neutralization of the infection and the increase of the virus capture, such as by the interaction of immune complexes with Fc receptors expressed in certain cell types. The creation of alternative routes of entry of the viral particle into cells by low-neutralizing antibodies, during secondary infections of flavivirus, results in increased levels of viral replication and pathogenicity. This mechanism constitutes a phenomenon called antibody-dependent enhancement (ADE) [24, 25].
\nDifferent studies have been conducted to understand the effects of cross-reactive memory antibodies on subsequent flavivirus exposures. Many of them reported that the opsonization of the virus with weakly neutralizing antibodies led to the increase of the viral production and of pro-inflammatory mediators. This could lead to the suppression of the antiviral immune response, worsening the clinical condition of the disease [5, 7]. ADE has already been reported in in vitro experiments of infection of cells that express Fc receptors and in vivo experiments of vaccination with flavivirus [11, 26]. From the results of these experiments, ADE is pointed out as one of the main causes of severe forms of DENV infection and of the low protection induced by vaccines targeting DENV serotypes [27].
\nAn opposite effect of cross-reacting antibodies has also been demonstrated, an increase in protection against secondary infections by flavivirus, which has resulted in potent neutralization and rapid induction of affinity maturing immune responses against heterologous flaviviruses. Studies in endemic areas of flavivirus showed protection against Zika virus infection in patients with a previous experience with DENV. A humoral response capable of potentially neutralizing both species of flavivirus was assembled from the expansion of cross-reaction memory B cell clones, even in the absence of DENV circulation. Thus, previous flavivirus infections can lead to both cross-neutralization and increased pathogenicity of the virus through the formation of interspecific antibody memory [28, 29].
\nThe potential of cross-reaction immunity to trigger protection or pathology depends on the profile, quality, and magnitude of the immune responses induced by antibodies. The ADE reaction is a factor that should be considered in the development of therapeutic antibodies and vaccines for infections by flavivirus. Different approaches have been tested to shift the ADE profile to a cross-protection profile in heterogeneous infections of these viruses.
\nThe principle of the Phage Display is the presentation of libraries of molecules on the surface of a bacteriophage (phage), allowing the identification of a wide range of biomolecules, including peptides, antibodies, and other proteins. The Phage Display methodology was first described in 1985, by George Smith and colleagues. Through the expression (display) of polypeptides on the phage surface (phage) M13, it was possible to perform the mapping of antibody epitopes by screening them using random peptide libraries [30]. In 1990, McCafferty and colleagues [31] demonstrated that it was also possible to fuse genes that encode an entire antibody domain, in the form of a scFv to the sequence of one of the bacteriophage’s coat proteins. This approach allowed that this methodology could also be used for the selection of bacteriophages that recognize antigens.
\nLater, in 1994, Winter refined the Phage Display technology through a guided selection strategy of human antibody fragments from Phage Display repertoires for a single-antigen epitope, using rodent MAbs as a model [32]. The first all-human antibody produced, using Winter’s Phage Display technique, to be marketed for use in humans was adalimumab (Humira), approved by the United States Food and Drug Administration (FDA) in 2002 for the treatment of rheumatoid arthritis [33]. It is noteworthy that George P. Smith and Gregory P. Winter received the Nobel Prize in chemistry in 2018 for the Phage Display of peptides and antibodies (Nobel Prize, 2018), a true tool for molecular evolution in vitro emphasizing the importance of this technique in obtaining biomolecules for various applications.
\nPhages are single-stranded viruses that infect Gram-negative bacteria and are used mainly for the purpose of gene cloning and expression of recombinant proteins, in addition to basic molecular biology studies. The particle coating is composed of five different proteins, pIII, pVI, pVII, pVIII, and pIX; proteins responsible for DNA replication include pII, pV, and pX; and the assembly proteins are pI, pIV, and pXI. All of the five proteins contribute to the stability of the phage particle; however, pIII is also necessary for the recognition and infection of the host cell [33]. Through genetic manipulation, sequences of billions of peptides, protein variants, and antibody fragments can be cloned into a vector associated with the phage coat protein gene, the pIII protein being the most commonly used [34]. Thus, the Phage Display methodology explores the possibility of direct binding of a certain protein (phenotype) with its cognate gene (genotype) by means of a phage [35].
\nBeyond the Phage Display and hybridoma technique, other strategies used for MAb production include immortalization of human B lymphocyte isolated from naturally infected or immunized individuals. One of the approaches for B lymphocyte immortalization is using Epstein-Barr virus (EBV). EBV is a human tumor virus that was shown to infect efficiently human B lymphocytes and induce continuous proliferation in vitro, opening a new perspective for the production of human MAbs [36]. Another relevant alternative for MAb production involves transgenic animals where mice are genetically manipulated to produce human immunoglobulin. In this strategy, genes of human immunoglobulins are inserted into mice genome replacing the endogenous sequences, making these animals capable to produce fully human antibodies when immunized with an antigen [37].
\nAmong the existing methodologies of antibody production, the hybridoma technique remains the most widely used. However, the production steps are laborious and dependent on the animal immune system. In addition, the heterologous character of these proteins often makes them immunogenic to humans, provoking the response of human anti-mouse antibodies (HAMA), which restrict their therapeutic use [34]. Therefore, the Phage Display has emerged as one of the main alternatives for the generation of human recombinant MAbs. The major advantages of using the Phage Display, in contrast to the hybridoma technique, are clearly the absence of the use of animals in the process and the less time to obtain antibodies. The conventional method requires immunization which, depending on the type of antigen, can take weeks to produce sufficient immune response to produce specific antibodies [38].
\nThere are important advantages and disadvantages between techniques for obtaining human MAbs. With the Phage Display technology, it is possible to isolate antibodies against all types of antigens, even those with high complexity; differently, the immortalization technique of human lymphocytes does not allow the isolation of antibodies against own antigens or non-immunogenic antigens [39]. In addition, only the Phage Display allows the optimization of MAbs, for example, by affinity maturation, and in general, the development of antibodies on the Phage Display tends to be faster than in other methods [40].
\nIn addition to being robust due to the high stability of the phage, the Phage Display also allows control over biochemical parameters throughout the selection process. The particular advantage of having control over biochemical parameters during the time of selection can also be used to shape the specificity profile of an antibody from the start [41]. Table 1 described the MAbs with FDA approval that was developed using the Phage Display technique.
\nAntibody | \nTarget | \nFormat | \nIndication | \nCompany | \nYear | \n
---|---|---|---|---|---|
Humira adalimumab | \nTNF-α | \nHuman | \nRheumatoid arthritis and Crohn’s disease | \nAbbott | \n2002 | \n
Lucentis Ranibizumab | \nVEGF-A | \nHumanized | \nMacular degeneration | \nGenentech | \n2006 | \n
Simponi Golimumab | \nTNF-α | \nHuman | \nRheumatoid arthritis | \nJohnson & Johnson | \n2009 | \n
Benlysta Belimumab | \nBLys | \nHuman | \nSystemic lupus erythematosus | \nGSK | \n2011 | \n
Pending Raxibacumab | \nPA | \nHuman | \nAnthrax infection (Bacillus anthracis) | \nGSK | \n2012 | \n
Cyramza Ramucirumab | \nVEGFR2 | \nHuman | \nGastric cancer | \nLilly | \n2014 | \n
Bavencio Avelumab | \nPD-L1 | \nHuman | \nMerkel cell carcinoma | \nSerono | \n2017 | \n
Tremfya Guselkumab | \nIL-23 | \nHuman | \nPlaque psoriasis | \nJanssen Biotech | \n2017 | \n
Gamifant Emapalumab | \nIFNγ | \nHuman | \nHemophagocytic lymphohistiocytosis | \nSwiss | \n2018 | \n
Monoclonal antibodies obtained by Phage Display with FDA approval.
TNF-α, tumor necrosis factor alpha; VEGF-A, vascular endothelial growth factor A; BLys, B lymphocyte stimulator; PA, protective antigen; VEGFR2, vascular endothelial growth factor receptor 2; PD-L1, programmed death-ligand 1; IL-23, interleukin-23; IFNγ, interferon-γ
Since 1990, different antibody formats have been employed in the construction of antibody Phage Display libraries (APDLs). Although antibody libraries are one of the most successful tools of Phage Display, the appropriate choice of antibody library is an important step for the success of antibody selection. Full-length antibodies in the immunoglobulin format are large (150 kDa), complex, and not suitable for Phage Display. Therefore, smaller antigen-binding fragments are used. For this reason, APDLs are in most cases constructed in either scFv (25 kDa), Fab (50 kDa), or single-domain antibody (sdAb) formats which are smaller and more effective, although each antibody format has its own advantages and limitations [42]. Particularly, sdAbs have received a growing interest as a promising antibody class compared with those conventional. Their more hydrophilic structure, easy molecular manipulation, convex surface, and long CDRs enable them to recognize cryptic and inaccessible epitopes for typical antibody fragments [43].
\nThere are many kinds of APDLs; they can be classified into two main types: natural APDL and synthetic APDL. This classification is based on the source of VH and VL genes. Natural APDL comprises immune libraries and naïve libraries, while synthetic APDLs comprise semisynthetic libraries and fully synthetic libraries [44]. The immune libraries use V-genes that already passed to the clonal selection and encode antibodies with high affinity and specificity against the target antigen. The immune APDLs have some advantages compared to other libraries, once they have the possibility to be explored for understanding the humoral responses in the specific disease. However, some limitations regarding this library are associated with the toxicity of some antigens and some ethical issues, which consequently impair the feasibility to active immunization of humans or other animals for obtention of antibody repertoires [41, 44].
\nThe naïve APLD involves the generation of libraries that allows the discovery of MAbs against all types of antigen. These libraries are produced through the repertoires of healthy donors, and antibody genes contained have much more diversity than immune libraries. The main advantage of using naïve libraries is the possibility to isolate MAbs against non-immunogenic and toxic antigens. However, the major drawback is that the selected MAbs often have low affinities compared with antibodies from immune libraries [33]. The semisynthetic APLD is based on the display of artificially made diversity in V-gene segments, usually by in vitro randomization of CDRs from a limited number of naïve variable regions, reconstructing the V-gene repertoires [41]. One of the characteristics of these libraries is the absence of natural biases and redundancies usually found in a naïve library. Unlike semisynthetic APDLs, the fully synthetic library is constructed through the incorporation of nucleotide randomization based on in silico design and de novo synthesis. This refined synthesis appears to increase the functional size of library and consequently the isolation of MAbs with a great range of affinity. However, they still need to be optimized regarding their binding sites, affinity, valency, and other characteristics [41, 44].
\nExcept in the case of fully synthetic libraries, generally, the construction of an antibody library is based on the amplification of the repertoire of the variable chain genes of one or more individuals using primers that cover all families of this gene. Subsequently, a random combination of the VL and VH chain is generated. In the case of the production of Fab libraries, a step is taken to join each variable chain fragment with its respective constant region. The PCR products of these amplifications, representing the antibody repertoire, are ligated into a phagemid vector and transformed into E. coli. However, phage vectors generally have only the origin of replication of the phage; they do not contain all the genes necessary for replication and assembly of these phages. Thus, screening libraries using this phagemid requires a helper phage to provide replication and assembly proteins. The addition of the phage to the bacterial cells transformed with the phagemid will result in the production of a mixture of phages that will present predominantly the phagemid vector [45].
\nOnce assembled, each phage exposes a fragment of functional antibody fused to one of the phage surface proteins [46, 47]. A determining factor for the quality of a library and consequently the success of a biopanning by Phage Display is its initial diversity, given by the number of different antibodies in the library. The greater the initial diversity of clones within the library, the greater the likelihood of containing sequences that will bind to a given target with greater affinity [45]. The capacity to produce very large libraries (1012 different clones) has turned the Phage Display into a fast and reliable high-throughput screening methodology [43].
\nMost biopanning methods are based on four main steps, preparing a library; incubation of that library with a given antigen; removal of nonspecific or low-affinity phages; and recovery of binding targets, which will be amplified after infection in E. coli and used in the next biopanning cycle (Figure 2). The Phage Display biopanning process is characterized by an increase in the number of clones with affinity for the target molecule through successive selection cycles, with a consequent reduction in the diversity of clones and in the presence of clones with low affinity [48]. Thus, the biopanning results in the sequential enrichment of phages that have a specific binding to the antigen.
\nBiopanning steps. Representation of a biopanning process characterized by a step of Phage Display library incubation with the target antigen, removal of unbound phages, elution of bound phages, and phage amplification in E. coli, followed by another cycle. After 3–5 cycles post-selection step is carried out.
These biopanning steps are usually repeated three to five times, until a high specificity/affinity ligand is identified [34, 45, 46]. During biopanning, phage binding to the antigen is retained on the plate, and, after a series of washes, these phages are eluted and amplified. Subsequently, the phages are again incubated with the antigen in the next cycle. Phages with low affinity for antigens may stick to the plate, not interacting with the particle, or remain suspended in the solution. After the wash step, many of these nonspecific phages are removed. Generally, this step involves the application of a greater wash stringency in each subsequent round, which can be performed by increasing the number of washes or increasing the concentration of the nonionic detergent buffer used.
\nDuring the biopanning stage, it is possible to monitor the enrichment of antibodies by measuring the phage titers that enter the selection and the phage titers that are eluted, assessing the enrichment ratio at each selection cycle. The enrichment follow-up provides the assurance that the selection was carried out efficiently and is followed by the analysis of the selection progress and the identification of the antibodies that have greater affinity to the target antigen [49]. Over the decades, different ways of analyzing selection have been reported, depending on the selection system employed, the antibody library used, and the antigen of interest. However, two methods stand out for the quality of the results they offer, a monoclonal analysis of a sample of the selected antibodies and a polyclonal analysis of the sequences of the entire antibody population.
\nFrom the population of selected phages or using cultures of the selected soluble antibodies, the specific binding of individual clones to the immobilized antigen is assessed in an ELISA assay. In this monoclonal ELISA, the binding of 30–100, or more, randomly chosen clones is compared with each other and with the negative control. Phages with the highest absorbance values are considered the ones that have displayed functionally antibodies of greater affinity. Positive clones for the binding analysis are subjected to a Sanger sequencing reaction to determine the sequences of the antibodies [50, 51, 52]. In this type of Phage Display analysis, the phenotypes (activity) of the antibodies are investigated first and then their genotype is determined. The disadvantage of this type of analysis is that it does not allow exploring the antibody population in depth and may not include all antibodies of greater affinity. In addition, it does not allow the study of the magnitude of selection and enrichment [53].
\nA high-throughput sequencing provides a tool for rapid analysis of the selection and direct identification of the most enriched antibodies, with greater affinity, without requiring a step of their expression. In addition to the speed of analysis, it is possible to investigate the original diversity of the library; identify all antibodies that enriched, the most enriched, and the rare in the population; and determine the frequency of increase throughout the selection. This is possible because sequencing technologies, called next-generation sequencing (NGS), are used, and they allow sequencing a large number of sequences, in the order of millions, in the same sequencing reaction [54]. The interpretation of NGS results from antibody libraries requires the use of a bioinformatics tool specialized in calculating the enrichment of variable domains in a selection of Phage Display. Different tools for this purpose are described in the literature, such as the recent ATTILA pipeline [55].
\nDespite providing a profound assessment of all antibodies in all cycles, two major problems arise in the analysis of biopanning by sequencing. The first corresponds to the noise in the identified final sequences that results from the sequencing process or the gene amplification reaction. However, more accurate pipelines for isolating DNA libraries for sequencing and more powerful bioinformatics analysis programs have been produced to overcome the artifacts introduced by PCR and sequencing errors. The second is the limitation of the high-performance sequencing methodology that, although it allows the sequencing of millions of sequences, can only properly read up to 400 base pairs. Therefore, this analysis requires that the variable domains of the heavy and light chain of antibodies, whose size ranges from 300 to 400 base pairs, be amplified and sequenced separately, resulting in the loss of the VH and VL pairs of the most enriched antibodies. Recently, studies have been carried out to provide a method of sequencing without losing the VH and VL pairs of antibodies. In the analysis of the selection process by a high-throughput sequencing, the antibody’s genotype is first determined and then their phenotype is characterized [53, 56, 57].
\nThe use of MAbs against an infection pathogen is an area of great interest for research. In Table 2 it is demonstrated MAbs developed for infection disease who have been approved by the FDA. As can be seen, few MAbs are approved for use in infectious diseases, although there is still a strong demand for development in this field. Some challenges involving MAb production against pathogens are their economic viability due to their high cost and if target an episodic disease, there is no supporting for continued production. Moreover, there is a concern about the selection of neutralization-escape mutants [58]. However, they may be notably effective for certain emerging infectious diseases, in which the process of vaccine development could be lengthened and difficult. Thus, MAbs should have more effectiveness for the first response against these diseases [57].
\nAntibody | \nTarget | \nFormat | \nIndication | \nCompany | \nYear | \nMethod | \n|
---|---|---|---|---|---|---|---|
Pending Raxibacumab | \nPA | \nHuman | \nAnthrax infection (Bacillus anthracis) | \nGSK | \n2012 | \nPhage Display | \n|
Zinplava Bezlotoxumab | \nToxin B | \nHuman | \n\nClostridium difficile infection | \nMerck/Dohme | \n2016 | \nTransgenic mice | \n|
Trogarzo Ibalizumab | \nCD4 | \nHumanized | \nHIV infection | \nTaiMed | \n2018 | \nHybridoma | \n|
Synagis Palivizumab | \nRSV F | \nHumanized | \nRespiratory syncytial virus (RSV) prophylaxis | \nMedImmune | \n1998 | \nHybridoma | \n
Monoclonal antibodies for infectious diseases approved by the FDA.
PA, protective antigen; CD4, cluster of differentiation 4; RSV F, respiratory syncytial virus fusion
Small molecules are most antibiotic antivirals. However, Phage Display-derived MAbs have an overall success rate of 35% of passage from clinical phase I to launch, compared to an average of 12% for a small-molecule drug candidate [59]. In this regard, Phage Display-derived MAb is considered an important alternative approach to infectious disease treatment compared to classical small-molecule discovery. Raxibacumab is an example of a fast-track designation from the FDA, providing the expedition of the drug to use against B. anthracis infection. This bacterium secretes proteins, the lethal factor and the edema factor, that inhibit normal immune system functioning that ultimately cause cell death. The entry of these factors is mediated by the protective antigen (PA), also secreted by the bacteria. Raxibacumab is directed to B. anthracis PA and thus prevents the cellular uptake of the lethal factor and edema factor. The MAb was developed by the Phage Display, using a library licensed by Human Genome Sciences (HGS), which now is GlaxoSmithKline (GSK), from Cambridge Antibody Technology. Recombinant PA was used in the biopanning process to select candidates, which were then screened in assays for PA neutralization [60, 61].
\nThe Phage Display technology provides a rapid methodology for building a high-affinity antibody library from immune repertoires. These antibodies can be used to generate diagnostic bases or be tested for therapeutic capability. For example, from the repertoire of B cells of patients who recovered from influenza virus infections or who received vaccination, it was possible to isolate, by Phage Display, several antibodies with the neutralization property of different influenza virus subtypes. Another example of antibody-based immunotherapy developed by Phage Display involves the identification of antibodies specific to different types of coronavirus. These studies are an example of how Phage Display enables the selection of antibodies by an in vitro process, especially for new or mutated pathogens in an outbreak of emergent infectious diseases, as it uses only pathogen-specific antigens [39, 62, 63].
\nParticularly, MAbs play an important role in antiviral immunity preventing viral replication and disease progress. Antibodies can interfere with virus infection by various mechanisms. The primary mechanism is by targeting the virus surface proteins; antibodies can inhibit virus attachment to cell surface receptors. Another main mechanism is targeting non-receptor-binding regions, such as in endosomal membrane fusion step where neutralization can occur by interfering virus conformational changes. In general, flavivirus particles tend to display on their surface continuum epitopes that induce potently neutralizing antibodies, blocking viral entry into cells [58].
\nFrom the understanding of the structure of each flavivirus, it was possible to determine the antibody targets most conducive to the diagnosis and protection of the disease [64]. It is important to note that flaviviruses are not static particles and viral proteins are in a constant dynamic movement, a process known as breathing, in order to transiently reveal new epitopes, and this characteristic influences the detection and neutralization capabilities of antibodies [10].
\nSo far, no MAbs against flavivirus have reached the clinical stages, except for WNV. However, several studies have demonstrated potentially neutralizing MAbs that could be therapeutically used against these infections [65, 66]. Different antibodies have been generated exploring the characteristics of viral epitopes. The E glycoprotein is the main target of neutralizing antibodies, especially the E DIII has been described to be the most efficient to block adsorption of DENV in vitro [58]. In the field of DENV diagnosis, MAbs have been especially applied to distinguish DENV serotypes [67, 68]. For this purpose E and soluble NS1 proteins are the main targets of these MAbs using different assay formats, such as ELISA and rapid test based on immunochromatography [69].
\nThe pre-existing cross-reactive antibodies can be boosted in a secondary infection with antigenically related molecules; consequently antibody to fusion loop tends to have dominance upon sequential infections with DENV or other flaviviruses. Antibodies to E-dimer epitope (EDE) are divided into two subclasses, EDE1 and EDE2, based on the recognition of the conserved glycan Asn-153 of DENV [58]. EDE1 has already been shown to potently neutralize ZIKV infection; this class of antibody does not require glycosylation for binding [70]. However, EDE2 have a reduced neutralization potential against ZIKV, once these antibodies have a strongly binding dependence on the glycan, which have different positioning between ZIKV and DENV [66].
\nThe generation of monoclonal antibodies by Phage Display can help improve the speed at which new antibodies are produced. The freedom associated with recombinant antibodies also allows them to be customized for various applications, allowing the development of MAbs with binding, functional, and pharmacological characteristics suitable for a therapeutic and diagnostic use [37]. Thus, the use of Phage Display to identify antibodies against DENV, as well as for other flavivirus, can contribute to the knowledge of the specific antigenic properties of the virus, allowing to generate new perspectives for the development of efficient therapies, vaccines, and diagnostic platforms of this virus.
\nTo obtain specific antibodies to the DENV, it is possible to employ different libraries of Phage Display and distinct selection approaches depending on the purpose. Using a llama immune library, a diagnostic methodology was developed based on antibodies capable of binding to the NS1 of the four DENV serotypes, without cross-reacting with NS1 of other flaviviruses. The panning was performed with immobilized antigen, so that in each round, the phage population was incubated with NS1 from one of the serotypes, resulting in phage specific to all forms of NS1. To characterize the diagnostic potential of the antibodies, MAbs were addressed [71]. Lebani et al. [72] isolate four serotype-specific human antibodies through a negative selection strategy. Each MAb was specific for NS1 from a DENV serotype, without cross-linking.
\nIn another approach, Cabezas et al. [73] worked with human naïve library to obtain a panel of antibody fragments with different specificity toward DENV serotypes. The biopanning was made against inactivated DENV-containing supernatants harvested from infected Vero cells for 4 days with each serotype. These supernatants were directly used for Phage Display biopanning. A panel of nine scFvs, where seven were specific for DENV2, DENV3, and DENV4 while the other two were cross-reactive, was obtained. Silva [74] employed a subtractive biopanning, in which a human Fab Phage Display library was first incubated against ZIKV particles, to eliminate the majority of antibodies that binds to this viral particle, and nonbinding phages were then incubated against DENV2 particles, followed by elution of ligand phages. Analysis by NGS of the pool of phages retrieved after four rounds of this biopanning showed that the VH and VL sequences obtained may not have cross-reactivity between DENV2 and ZIKV.
\nAntibody-based DENV infection therapies developed by Phage Display have also been reported. Saokaew et al. [75] show that a human scFv specific for DIII was able to neutralize DENV2 infection at in vitro assays. The human MAb 5A, originated from a selection of Phage Display, has been shown to be specific to the fusion loop, both in its pre-fusion conformation to the endocytic membrane, before infection, and in its acid-dependent post-fusion conformation, during the final viral infection process, and proved to be a potent neutralizing antibody of different strains of yellow fever virus in vitro and in vivo. Thus, MAb 5A prevents both virus attachment and fusion. As the fusion loop is a highly conserved antigen, there is a high possibility that 5A neutralizes other flaviviruses [76]. In the same way, Wu et al. [77] identified a panel of human MAbs that target DIII of the ZIKV envelope protein from a large Phage Display naïve antibody library. These germline-like antibodies bound ZIKV DIII specifically with high affinities. These MAbs neutralized the currently circulating ZIKV strains and showed a synergistic effect in neutralizing ZIKV in vitro and in a mouse model of ZIKV infection.
\nAs an example of Phage Display using immune libraries to select high-affinity MAbs, Mwale et al. [78] analyzed the immune response in chicken through the determination of the polyclonal immunoglobulin yolk (IgY) against a truncated Zika virus envelope protein. They induced an immune response in white leghorn laying hens against the ZIKV envelope protein. A high-level titer of anti-ZIKV envelope protein antibodies was detected and after constructed two antibody libraries; they found some scFvs that showed specific binding activities toward the ZIKV envelope protein.
\nMoreover, Phage Display has been used to find therapeutic antibody fragments against nonstructural proteins. A MAb fragment Fab NS3-specific obtained from a naïve human Fab Phage Display library was shown to inhibit the ATPase and helicase activities of NS3 protein and reduces DENV replication in vitro. The ability to inhibit in vitro DENV replication may be exploited in a therapeutic approach [79]. Using a human scFv Phage Display library, Poungpair et al. [80] obtained two scFv clones that bound specifically to the NS1 of DENV 2, used as antigen in phage biopanning. They observed that cells infected with DENV2 and treated with selected scFvs had significant reduction of the infectious viral particles in supernatant. Besides that, the analysis of mimotope/epitope mapping indicated that the NS1 sites bound by antibody fragments can lead to interference of the virus replication by affecting the virus release.
\nOver the years many discoveries have been made aiming for the control and treatment of emerging infectious diseases, some of those include the development of efficient drugs that could act specifically in the pathogen to eliminate efficiently. In this way, MAbs emerged as the main biological drugs for this purpose. Moreover, MAbs play an important role in the development of serological diagnostic test that could be used for tracking the spread of disease and determining public health prevention measures and clinical care. There are still great questions around the infection mechanisms by flavivirus, especially related to the cross-reactivity between them and the risk of complications. In this way, the use of effective, fast, and robust approaches to facilitate the development of flavivirus MAbs is a determinant factor.
\nThe Phage Display technology presents a great potential to provide optimized strategies, allowing the obtention of high-affinity human antibodies for a specific target. Some of the main advantages that make this technology so promising are the possibility to obtain human MAbs without in vivo immunization; the enormous diversity of variant antibodies displayed within a single library; the ability to tailor MAbs with the desired properties by using different strategies such as depletion, guided selection, and biochemical control; and the possibility to be applied against practically any kind of target antigen [33]. However, some concerns about Phage Display are the dependence of the initial library quality, the difficulties in the post-selection step involving analysis and recombinant antibody production, and the possibility of obtention of low-affinity antibodies, especially in naïve libraries [35]. Considering the impact of infectious diseases on the health system and economy, mainly DENV and ZIKV, that co-circulate in tropical countries, MAbs obtained by Phage Display may overcome issues related to versatility and high throughputness compared to other approaches, playing a larger role in the actual and future public health response.
\nThe authors would like to thank the Immunology Department of Adolfo Lutz Institute, the Coordination of Improvement of Postgraduate Level Personnel (CAPES), and the National Council for Scientific and Technological Development (CNPq). The authors also thank the Cellular Biology Department from the University of Brazilia, Post-Graduate Program in Molecular Biology (UNB), and Foundation for Scientific and Technological Enterprises (FINATEC) for the financial and technical support. This study was financed under grant CNPq/CAPES/MS-DECIT No. 440812/2016-0 and FINEP under sgrant No. 01.16.0075, under the coordination of Dr. Carlos R. Prudencio.
\nThe authors declare no conflict of interest.
IntechOpen aims to guarantee that original material is published while at the same time giving significant freedom to our Authors. We uphold a flexible Copyright Policy, guaranteeing that there is no transfer of copyright to the publisher and Authors retain exclusive copyright to their Work.
',metaTitle:"Publication Agreement - Monograph",metaDescription:"IntechOpen aims to guarantee that original material is published while at the same time giving significant freedom to our authors. For that matter, we uphold a flexible copyright policy meaning that there is no transfer of copyright to the publisher and authors retain exclusive copyright to their work.",metaKeywords:null,canonicalURL:"/page/publication-agreement-monograph",contentRaw:'[{"type":"htmlEditorComponent","content":"When submitting a manuscript, the Author is required to accept the Terms and Conditions set out in our Publication Agreement – Monographs/Compacts as follows:
\\n\\nCORRESPONDING AUTHOR'S GRANT OF RIGHTS
\\n\\nSubject to the following Article, the Author grants to IntechOpen, during the full term of copyright, and any extensions or renewals of that term, the following:
\\n\\nThe foregoing licenses shall survive the expiry or termination of this Publication Agreement for any reason.
\\n\\nThe Author, on his or her own behalf and on behalf of any of the Co-Authors, reserves the following rights in the Work but agrees not to exercise them in such a way as to adversely affect IntechOpen's ability to utilize the full benefit of this Publication Agreement: (i) reprographic rights worldwide, other than those which subsist in the typographical arrangement of the Work as published by IntechOpen; and (ii) public lending rights arising under the Public Lending Right Act 1979, as amended from time to time, and any similar rights arising in any part of the world.
\\n\\nThe Author, and any Co-Author, confirms that they are, and will remain, a member of any applicable licensing and collecting society and any successor to that body responsible for administering royalties for the reprographic reproduction of copyright works.
\\n\\nSubject to the license granted above, copyright in the Work and all versions of it created during IntechOpen's editing process, including all published versions, is retained by the Author and any Co-Authors.
\\n\\nSubject to the license granted above, the Author and Co-Authors retain patent, trademark and other intellectual property rights to the Work.
\\n\\nAll rights granted to IntechOpen in this Article are assignable, sublicensable or otherwise transferrable to third parties without the specific approval of the Author or Co-Authors.
\\n\\nThe Author, on his/her own behalf and on behalf of the Co-Authors, will not assert any rights under the Copyright, Designs and Patents Act 1988 to object to derogatory treatment of the Work as a consequence of IntechOpen's changes to the Work arising from the translation of it, corrections and edits for house style, removal of problematic material and other reasonable edits as determined by IntechOpen.
\\n\\nAUTHOR'S DUTIES
\\n\\nWhen distributing or re-publishing the Work, the Author agrees to credit the Monograph/Compacts as the source of first publication, as well as IntechOpen. The Author guarantees that Co-Authors will also credit the Monograph/Compacts as the source of first publication, as well as IntechOpen, when they are distributing or re-publishing the Work.
\\n\\nThe Author agrees to:
\\n\\nThe Author will be held responsible for the payment of the agreed Open Access Publishing Fee before the completion of the project (Monograph/Compacts publication).
\\n\\nAll payments shall be due 30 days from the date of issue of the invoice. The Author or whoever is paying on behalf of the Author and Co-Authors will bear all banking and similar charges incurred.
\\n\\nThe Author shall obtain in writing all consents necessary for the reproduction of any material in which a third-party right exists, including quotations, photographs and illustrations, in all editions of the Work worldwide for the full term of the above licenses, and shall provide to IntechOpen, at its request, the original copies of such consents for inspection or the photocopies of such consents.
\\n\\nThe Author shall obtain written informed consent for publication from those who might recognize themselves or be identified by others, for example from case reports or photographs.
\\n\\nThe Author shall respect confidentiality during and after the termination of this Agreement. The information contained in all correspondence and documents as part of the publishing activity between IntechOpen and the Author and Co-Authors are confidential and are intended only for the recipients. The contents of any communication may not be disclosed publicly and are not intended for unauthorized use or distribution. Any use, disclosure, copying, or distribution is prohibited and may be unlawful.
\\n\\nAUTHOR'S WARRANTY
\\n\\nThe Author and Co-Authors confirm and warrant that the Work does not and will not breach any applicable law or the rights of any third party and, specifically, that the Work contains no matter that is defamatory or that infringes any literary or proprietary rights, intellectual property rights, or any rights of privacy.
\\n\\nThe Author and Co-Authors confirm that: (i) the Work is their original work and is not copied wholly or substantially from any other work or material or any other source; (ii) the Work has not been formally published in any other peer-reviewed journal or in a book or edited collection, and is not under consideration for any such publication; (iii) Authors and any applicable Co-Authors are qualifying persons under section 154 of the Copyright, Designs and Patents Act 1988; (iv) Authors and any applicable Co-Authors have not assigned, and will not during the term of this Publication Agreement purport to assign, any of the rights granted to IntechOpen under this Publication Agreement; and (v) the rights granted by this Publication Agreement are free from any security interest, option, mortgage, charge or lien.
\\n\\nThe Author and Co-Authors also confirm and warrant that: (i) he/she has the power to enter into this Publication Agreement on his or her own behalf and on behalf of each Co-Author; and (ii) has the necessary rights and/or title in and to the Work to grant IntechOpen, on behalf of themselves and any Co-Author, the rights and licences in this Publication Agreement. If the Work was prepared jointly by the Author and Co-Authors, the Author confirms that: (i) all Co-Authors agree to the submission, license and publication of the Work on the terms of this Publication Agreement; and (ii) the Author has the authority to enter into this biding Publication Agreement on behalf of each Co-Author. The Author shall: (i) ensure each Co-Author complies with all relevant provisions of this Publication Agreement, including those relating to confidentiality, performance and standards, as if a party to this Publication Agreement; and (ii) remain primarily liable for all acts and/or omissions of each Co-Author.
\\n\\nThe Author agrees to indemnify IntechOpen harmless against all liabilities, costs, expenses, damages and losses, as well as all reasonable legal costs and expenses suffered or incurred by IntechOpen arising out of, or in connection with, any breach of the agreed confirmations and warranties. This indemnity shall not apply in a situation in which a claim results from IntechOpen's negligence or willful misconduct.
\\n\\nNothing in this Publication Agreement shall have the effect of excluding or limiting any liability for death or personal injury caused by negligence or any other liability that cannot be excluded or limited by applicable law.
\\n\\nTERMINATION
\\n\\nIntechOpen has the right to terminate this Publication Agreement for quality, program, technical or other reasons with immediate effect, including without limitation (i) if the Author and/or any Co-Author commits a material breach of this Publication Agreement; (ii) if the Author and/or any Co-Author (being a private individual) is the subject of a bankruptcy petition, application or order; or (iii) if the Author and/or any Co-Author (as a corporate entity) commences negotiations with all or any class of its creditors with a view to rescheduling any of its debts, or makes a proposal for, or enters into, any compromise or arrangement with any of its creditors.
\\n\\nIn the event of termination, IntechOpen will notify the Author of the decision in writing.
\\n\\nIntechOpen’s DUTIES AND RIGHTS
\\n\\nUnless prevented from doing so by events beyond its reasonable control, IntechOpen, at its discretion, agrees to publish the Work attributing it to the Author and Co-Authors.
\\n\\nUnless prevented from doing so by events beyond its reasonable control, IntechOpen agrees to provide publishing services which include: managing editing (editorial and publishing process coordination, Author assistance); publishing software technology; language copyediting; typesetting; online publishing; hosting and web management; and abstracting and indexing services.
\\n\\nIntechOpen agrees to offer free online access to readers and use reasonable efforts to promote the Publication to relevant audiences.
\\n\\nIntechOpen is granted the authority to enforce the rights from this Publication Agreement on behalf of the Author and Co-Authors against third parties, for example in cases of plagiarism or copyright infringements. In respect of any such infringement or suspected infringement of the copyright in the Work, IntechOpen shall have absolute discretion in addressing any such infringement that is likely to affect IntechOpen's rights under this Publication Agreement, including issuing and conducting proceedings against the suspected infringer.
\\n\\nIntechOpen has the right to include/use the Author and Co-Authors names and likeness in connection with scientific dissemination, retrieval, archiving, web hosting and promotion and marketing of the Work and has the right to contact the Author and Co-Authors until the Work is publicly available on any platform owned and/or operated by IntechOpen.
\\n\\nMISCELLANEOUS
\\n\\nFurther Assurance: The Author shall ensure that any relevant third party, including any Co-Author, shall execute and deliver whatever further documents or deeds and perform such acts as IntechOpen reasonably requires from time to time for the purpose of giving IntechOpen the full benefit of the provisions of this Publication Agreement.
\\n\\nThird Party Rights: A person who is not a party to this Publication Agreement may not enforce any of its provisions under the Contracts (Rights of Third Parties) Act 1999.
\\n\\nEntire Agreement: This Publication Agreement constitutes the entire agreement between the parties in relation to its subject matter. It replaces all prior agreements, draft agreements, arrangements, collateral warranties, collateral contracts, statements, assurances, representations and undertakings of any nature made by, or on behalf of, the parties, whether oral or written, in relation to that subject matter. Each party acknowledges that in entering into this Publication Agreement it has not relied upon any oral or written statements, collateral or other warranties, assurances, representations or undertakings which were made by or on behalf of the other party in relation to the subject matter of this Publication Agreement at any time before its signature (known as the "Pre-Contractual Statements"), other than those which are set out in this Publication Agreement. Each party hereby waives all rights and remedies which might otherwise be available to it in relation to such Pre-Contractual Statements. Nothing in this clause shall exclude or restrict the liability of either party arising out of any fraudulent pre-contract misrepresentation or concealment.
\\n\\nWaiver: No failure or delay by a party to exercise any right or remedy provided under this Publication Agreement or by law shall constitute a waiver of that or any other right or remedy, nor shall it preclude or restrict the further exercise of that or any other right or remedy. No single or partial exercise of such right or remedy shall preclude or restrict the further exercise of that or any other right or remedy.
\\n\\nVariation: No variation of this Publication Agreement shall have effect unless it is in writing and signed by the parties, or their duly authorized representatives.
\\n\\nSeverance: If any provision, or part-provision, of this Publication Agreement is, or becomes invalid, illegal or unenforceable, it shall be deemed modified to the minimum extent necessary to make it valid, legal and enforceable. If such modification is not possible, the relevant provision or part-provision shall be deemed deleted. Any modification to, or deletion of, a provision or part-provision under this clause shall not affect the validity and enforceability of the rest of this Publication Agreement.
\\n\\nNo partnership: Nothing in this Publication Agreement is intended to, or shall be deemed to, establish or create any partnership or joint venture or the relationship of principal and agent or employer and employee between IntechOpen and the Author or any Co-Author, nor authorize any party to make or enter into any commitments for, or on behalf of, any other party.
\\n\\nGoverning law: This Publication Agreement and any dispute or claim, including non-contractual disputes or claims arising out of, or in connection with it, or its subject matter or formation, shall be governed by and construed in accordance with the law of England and Wales. The parties submit to the exclusive jurisdiction of the English courts to settle any dispute or claim arising out of, or in connection with, this Publication Agreement, including any non-contractual disputes or claims.
\\n\\nPolicy last updated: 2018-09-11
\\n"}]'},components:[{type:"htmlEditorComponent",content:'When submitting a manuscript, the Author is required to accept the Terms and Conditions set out in our Publication Agreement – Monographs/Compacts as follows:
\n\nCORRESPONDING AUTHOR'S GRANT OF RIGHTS
\n\nSubject to the following Article, the Author grants to IntechOpen, during the full term of copyright, and any extensions or renewals of that term, the following:
\n\nThe foregoing licenses shall survive the expiry or termination of this Publication Agreement for any reason.
\n\nThe Author, on his or her own behalf and on behalf of any of the Co-Authors, reserves the following rights in the Work but agrees not to exercise them in such a way as to adversely affect IntechOpen's ability to utilize the full benefit of this Publication Agreement: (i) reprographic rights worldwide, other than those which subsist in the typographical arrangement of the Work as published by IntechOpen; and (ii) public lending rights arising under the Public Lending Right Act 1979, as amended from time to time, and any similar rights arising in any part of the world.
\n\nThe Author, and any Co-Author, confirms that they are, and will remain, a member of any applicable licensing and collecting society and any successor to that body responsible for administering royalties for the reprographic reproduction of copyright works.
\n\nSubject to the license granted above, copyright in the Work and all versions of it created during IntechOpen's editing process, including all published versions, is retained by the Author and any Co-Authors.
\n\nSubject to the license granted above, the Author and Co-Authors retain patent, trademark and other intellectual property rights to the Work.
\n\nAll rights granted to IntechOpen in this Article are assignable, sublicensable or otherwise transferrable to third parties without the specific approval of the Author or Co-Authors.
\n\nThe Author, on his/her own behalf and on behalf of the Co-Authors, will not assert any rights under the Copyright, Designs and Patents Act 1988 to object to derogatory treatment of the Work as a consequence of IntechOpen's changes to the Work arising from the translation of it, corrections and edits for house style, removal of problematic material and other reasonable edits as determined by IntechOpen.
\n\nAUTHOR'S DUTIES
\n\nWhen distributing or re-publishing the Work, the Author agrees to credit the Monograph/Compacts as the source of first publication, as well as IntechOpen. The Author guarantees that Co-Authors will also credit the Monograph/Compacts as the source of first publication, as well as IntechOpen, when they are distributing or re-publishing the Work.
\n\nThe Author agrees to:
\n\nThe Author will be held responsible for the payment of the agreed Open Access Publishing Fee before the completion of the project (Monograph/Compacts publication).
\n\nAll payments shall be due 30 days from the date of issue of the invoice. The Author or whoever is paying on behalf of the Author and Co-Authors will bear all banking and similar charges incurred.
\n\nThe Author shall obtain in writing all consents necessary for the reproduction of any material in which a third-party right exists, including quotations, photographs and illustrations, in all editions of the Work worldwide for the full term of the above licenses, and shall provide to IntechOpen, at its request, the original copies of such consents for inspection or the photocopies of such consents.
\n\nThe Author shall obtain written informed consent for publication from those who might recognize themselves or be identified by others, for example from case reports or photographs.
\n\nThe Author shall respect confidentiality during and after the termination of this Agreement. The information contained in all correspondence and documents as part of the publishing activity between IntechOpen and the Author and Co-Authors are confidential and are intended only for the recipients. The contents of any communication may not be disclosed publicly and are not intended for unauthorized use or distribution. Any use, disclosure, copying, or distribution is prohibited and may be unlawful.
\n\nAUTHOR'S WARRANTY
\n\nThe Author and Co-Authors confirm and warrant that the Work does not and will not breach any applicable law or the rights of any third party and, specifically, that the Work contains no matter that is defamatory or that infringes any literary or proprietary rights, intellectual property rights, or any rights of privacy.
\n\nThe Author and Co-Authors confirm that: (i) the Work is their original work and is not copied wholly or substantially from any other work or material or any other source; (ii) the Work has not been formally published in any other peer-reviewed journal or in a book or edited collection, and is not under consideration for any such publication; (iii) Authors and any applicable Co-Authors are qualifying persons under section 154 of the Copyright, Designs and Patents Act 1988; (iv) Authors and any applicable Co-Authors have not assigned, and will not during the term of this Publication Agreement purport to assign, any of the rights granted to IntechOpen under this Publication Agreement; and (v) the rights granted by this Publication Agreement are free from any security interest, option, mortgage, charge or lien.
\n\nThe Author and Co-Authors also confirm and warrant that: (i) he/she has the power to enter into this Publication Agreement on his or her own behalf and on behalf of each Co-Author; and (ii) has the necessary rights and/or title in and to the Work to grant IntechOpen, on behalf of themselves and any Co-Author, the rights and licences in this Publication Agreement. If the Work was prepared jointly by the Author and Co-Authors, the Author confirms that: (i) all Co-Authors agree to the submission, license and publication of the Work on the terms of this Publication Agreement; and (ii) the Author has the authority to enter into this biding Publication Agreement on behalf of each Co-Author. The Author shall: (i) ensure each Co-Author complies with all relevant provisions of this Publication Agreement, including those relating to confidentiality, performance and standards, as if a party to this Publication Agreement; and (ii) remain primarily liable for all acts and/or omissions of each Co-Author.
\n\nThe Author agrees to indemnify IntechOpen harmless against all liabilities, costs, expenses, damages and losses, as well as all reasonable legal costs and expenses suffered or incurred by IntechOpen arising out of, or in connection with, any breach of the agreed confirmations and warranties. This indemnity shall not apply in a situation in which a claim results from IntechOpen's negligence or willful misconduct.
\n\nNothing in this Publication Agreement shall have the effect of excluding or limiting any liability for death or personal injury caused by negligence or any other liability that cannot be excluded or limited by applicable law.
\n\nTERMINATION
\n\nIntechOpen has the right to terminate this Publication Agreement for quality, program, technical or other reasons with immediate effect, including without limitation (i) if the Author and/or any Co-Author commits a material breach of this Publication Agreement; (ii) if the Author and/or any Co-Author (being a private individual) is the subject of a bankruptcy petition, application or order; or (iii) if the Author and/or any Co-Author (as a corporate entity) commences negotiations with all or any class of its creditors with a view to rescheduling any of its debts, or makes a proposal for, or enters into, any compromise or arrangement with any of its creditors.
\n\nIn the event of termination, IntechOpen will notify the Author of the decision in writing.
\n\nIntechOpen’s DUTIES AND RIGHTS
\n\nUnless prevented from doing so by events beyond its reasonable control, IntechOpen, at its discretion, agrees to publish the Work attributing it to the Author and Co-Authors.
\n\nUnless prevented from doing so by events beyond its reasonable control, IntechOpen agrees to provide publishing services which include: managing editing (editorial and publishing process coordination, Author assistance); publishing software technology; language copyediting; typesetting; online publishing; hosting and web management; and abstracting and indexing services.
\n\nIntechOpen agrees to offer free online access to readers and use reasonable efforts to promote the Publication to relevant audiences.
\n\nIntechOpen is granted the authority to enforce the rights from this Publication Agreement on behalf of the Author and Co-Authors against third parties, for example in cases of plagiarism or copyright infringements. In respect of any such infringement or suspected infringement of the copyright in the Work, IntechOpen shall have absolute discretion in addressing any such infringement that is likely to affect IntechOpen's rights under this Publication Agreement, including issuing and conducting proceedings against the suspected infringer.
\n\nIntechOpen has the right to include/use the Author and Co-Authors names and likeness in connection with scientific dissemination, retrieval, archiving, web hosting and promotion and marketing of the Work and has the right to contact the Author and Co-Authors until the Work is publicly available on any platform owned and/or operated by IntechOpen.
\n\nMISCELLANEOUS
\n\nFurther Assurance: The Author shall ensure that any relevant third party, including any Co-Author, shall execute and deliver whatever further documents or deeds and perform such acts as IntechOpen reasonably requires from time to time for the purpose of giving IntechOpen the full benefit of the provisions of this Publication Agreement.
\n\nThird Party Rights: A person who is not a party to this Publication Agreement may not enforce any of its provisions under the Contracts (Rights of Third Parties) Act 1999.
\n\nEntire Agreement: This Publication Agreement constitutes the entire agreement between the parties in relation to its subject matter. It replaces all prior agreements, draft agreements, arrangements, collateral warranties, collateral contracts, statements, assurances, representations and undertakings of any nature made by, or on behalf of, the parties, whether oral or written, in relation to that subject matter. Each party acknowledges that in entering into this Publication Agreement it has not relied upon any oral or written statements, collateral or other warranties, assurances, representations or undertakings which were made by or on behalf of the other party in relation to the subject matter of this Publication Agreement at any time before its signature (known as the "Pre-Contractual Statements"), other than those which are set out in this Publication Agreement. Each party hereby waives all rights and remedies which might otherwise be available to it in relation to such Pre-Contractual Statements. Nothing in this clause shall exclude or restrict the liability of either party arising out of any fraudulent pre-contract misrepresentation or concealment.
\n\nWaiver: No failure or delay by a party to exercise any right or remedy provided under this Publication Agreement or by law shall constitute a waiver of that or any other right or remedy, nor shall it preclude or restrict the further exercise of that or any other right or remedy. No single or partial exercise of such right or remedy shall preclude or restrict the further exercise of that or any other right or remedy.
\n\nVariation: No variation of this Publication Agreement shall have effect unless it is in writing and signed by the parties, or their duly authorized representatives.
\n\nSeverance: If any provision, or part-provision, of this Publication Agreement is, or becomes invalid, illegal or unenforceable, it shall be deemed modified to the minimum extent necessary to make it valid, legal and enforceable. If such modification is not possible, the relevant provision or part-provision shall be deemed deleted. Any modification to, or deletion of, a provision or part-provision under this clause shall not affect the validity and enforceability of the rest of this Publication Agreement.
\n\nNo partnership: Nothing in this Publication Agreement is intended to, or shall be deemed to, establish or create any partnership or joint venture or the relationship of principal and agent or employer and employee between IntechOpen and the Author or any Co-Author, nor authorize any party to make or enter into any commitments for, or on behalf of, any other party.
\n\nGoverning law: This Publication Agreement and any dispute or claim, including non-contractual disputes or claims arising out of, or in connection with it, or its subject matter or formation, shall be governed by and construed in accordance with the law of England and Wales. The parties submit to the exclusive jurisdiction of the English courts to settle any dispute or claim arising out of, or in connection with, this Publication Agreement, including any non-contractual disputes or claims.
\n\nPolicy last updated: 2018-09-11
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"160349",title:null,name:null,middleName:null,surname:null,slug:"",fullName:null,position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"25887",title:"Dr.",name:null,middleName:null,surname:"Abbasi",slug:"abbasi",fullName:"Abbasi",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"161332",title:"Dr",name:null,middleName:null,surname:"Abu-El Hassan",slug:"abu-el-hassan",fullName:"Abu-El Hassan",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"212347",title:"Dr.",name:null,middleName:null,surname:"Abubakar",slug:"abubakar",fullName:"Abubakar",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"93806",title:"Dr",name:null,middleName:null,surname:"Adani",slug:"adani",fullName:"Adani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"158756",title:"Dr",name:null,middleName:null,surname:"Adler",slug:"adler",fullName:"Adler",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"63002",title:"Dr.",name:null,middleName:null,surname:"Agius",slug:"agius",fullName:"Agius",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"34637",title:"Dr.",name:null,middleName:null,surname:"Ahmed",slug:"ahmed",fullName:"Ahmed",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"118228",title:"Dr",name:null,middleName:null,surname:"Ahmed",slug:"ahmed",fullName:"Ahmed",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"89784",title:"Dr",name:null,middleName:null,surname:"Ai",slug:"ai",fullName:"Ai",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"158339",title:"Dr",name:null,middleName:null,surname:"Akahoshi",slug:"akahoshi",fullName:"Akahoshi",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"158540",title:"Dr",name:null,middleName:null,surname:"Al-Jumaily",slug:"al-jumaily",fullName:"Al-Jumaily",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5698},{group:"region",caption:"Middle and South America",value:2,count:5172},{group:"region",caption:"Africa",value:3,count:1689},{group:"region",caption:"Asia",value:4,count:10243},{group:"region",caption:"Australia and Oceania",value:5,count:888},{group:"region",caption:"Europe",value:6,count:15647}],offset:12,limit:12,total:117315},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{sort:"dateEndThirdStepPublish",topicId:"7"},books:[{type:"book",id:"10755",title:"Corporate Governance",subtitle:null,isOpenForSubmission:!0,hash:"33697a6f655fc4d7f4a21a0a083a9096",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10755.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10757",title:"Agricultural Value Chain",subtitle:null,isOpenForSubmission:!0,hash:"732ee82bf579a4bc4c5c929ceba2db26",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10757.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10753",title:"Taxes",subtitle:null,isOpenForSubmission:!0,hash:"9dc0293dca676c8e873312737c84b60c",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10753.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10551",title:"Beyond Human Resources - Research Paths Towards a New Understanding of Workforce Management Within Organizations",subtitle:null,isOpenForSubmission:!0,hash:"4a34551c1324fb084e902ad7f56e584d",slug:null,bookSignature:"Dr. Gonzalo Sánchez-Gardey, Dr. Fernando Martín-Alcázar and Dr. Natalia García-Carbonell",coverURL:"https://cdn.intechopen.com/books/images_new/10551.jpg",editedByType:null,editors:[{id:"332101",title:"Prof.",name:"Gonzalo",surname:"Sánchez",slug:"gonzalo-sanchez",fullName:"Gonzalo Sánchez"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9553",title:"Cryptocurrency Economy",subtitle:null,isOpenForSubmission:!0,hash:"2548b2dab88b36797382292832f86563",slug:null,bookSignature:"Dr. Sebahattin Demirkan",coverURL:"https://cdn.intechopen.com/books/images_new/9553.jpg",editedByType:null,editors:[{id:"336397",title:"Dr.",name:"Sebahattin",surname:"Demirkan",slug:"sebahattin-demirkan",fullName:"Sebahattin Demirkan"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10918",title:"Digital Economy",subtitle:null,isOpenForSubmission:!0,hash:"dbdfd9caf5c4b0038ff4446c7bc6a681",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10918.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10916",title:"Firm Value",subtitle:null,isOpenForSubmission:!0,hash:"0de75a8efe6a5f4c8d42858ca3016f08",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10916.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10919",title:"Consumer Behavior",subtitle:null,isOpenForSubmission:!0,hash:"51700695578f48743b0514ba6d8735b2",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10919.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10917",title:"Entrepreneurship",subtitle:null,isOpenForSubmission:!0,hash:"904717638ed1e5538792e4d431fe59a5",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10917.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10915",title:"Leadership",subtitle:null,isOpenForSubmission:!0,hash:"f8f21ec8134eff175fa49450269811d8",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10915.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:9},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:18},{group:"topic",caption:"Business, Management and Economics",value:7,count:2},{group:"topic",caption:"Chemistry",value:8,count:7},{group:"topic",caption:"Computer and Information Science",value:9,count:11},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:5},{group:"topic",caption:"Engineering",value:11,count:15},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:5},{group:"topic",caption:"Materials Science",value:14,count:4},{group:"topic",caption:"Mathematics",value:15,count:1},{group:"topic",caption:"Medicine",value:16,count:60},{group:"topic",caption:"Nanotechnology and Nanomaterials",value:17,count:1},{group:"topic",caption:"Neuroscience",value:18,count:1},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:6},{group:"topic",caption:"Physics",value:20,count:2},{group:"topic",caption:"Psychology",value:21,count:3},{group:"topic",caption:"Robotics",value:22,count:1},{group:"topic",caption:"Social Sciences",value:23,count:3},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:2}],offset:12,limit:12,total:10},popularBooks:{featuredBooks:[{type:"book",id:"7802",title:"Modern Slavery and Human Trafficking",subtitle:null,isOpenForSubmission:!1,hash:"587a0b7fb765f31cc98de33c6c07c2e0",slug:"modern-slavery-and-human-trafficking",bookSignature:"Jane Reeves",coverURL:"https://cdn.intechopen.com/books/images_new/7802.jpg",editors:[{id:"211328",title:"Prof.",name:"Jane",middleName:null,surname:"Reeves",slug:"jane-reeves",fullName:"Jane Reeves"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8545",title:"Animal Reproduction in Veterinary Medicine",subtitle:null,isOpenForSubmission:!1,hash:"13aaddf5fdbbc78387e77a7da2388bf6",slug:"animal-reproduction-in-veterinary-medicine",bookSignature:"Faruk Aral, Rita Payan-Carreira and Miguel Quaresma",coverURL:"https://cdn.intechopen.com/books/images_new/8545.jpg",editors:[{id:"25600",title:"Prof.",name:"Faruk",middleName:null,surname:"Aral",slug:"faruk-aral",fullName:"Faruk Aral"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9961",title:"Data Mining",subtitle:"Methods, Applications and Systems",isOpenForSubmission:!1,hash:"ed79fb6364f2caf464079f94a0387146",slug:"data-mining-methods-applications-and-systems",bookSignature:"Derya Birant",coverURL:"https://cdn.intechopen.com/books/images_new/9961.jpg",editors:[{id:"15609",title:"Dr.",name:"Derya",middleName:null,surname:"Birant",slug:"derya-birant",fullName:"Derya Birant"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9157",title:"Neurodegenerative Diseases",subtitle:"Molecular Mechanisms and Current Therapeutic Approaches",isOpenForSubmission:!1,hash:"bc8be577966ef88735677d7e1e92ed28",slug:"neurodegenerative-diseases-molecular-mechanisms-and-current-therapeutic-approaches",bookSignature:"Nagehan Ersoy Tunalı",coverURL:"https://cdn.intechopen.com/books/images_new/9157.jpg",editors:[{id:"82778",title:"Ph.D.",name:"Nagehan",middleName:null,surname:"Ersoy Tunalı",slug:"nagehan-ersoy-tunali",fullName:"Nagehan Ersoy Tunalı"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8686",title:"Direct Torque Control Strategies of Electrical Machines",subtitle:null,isOpenForSubmission:!1,hash:"b6ad22b14db2b8450228545d3d4f6b1a",slug:"direct-torque-control-strategies-of-electrical-machines",bookSignature:"Fatma Ben Salem",coverURL:"https://cdn.intechopen.com/books/images_new/8686.jpg",editors:[{id:"295623",title:"Associate Prof.",name:"Fatma",middleName:null,surname:"Ben Salem",slug:"fatma-ben-salem",fullName:"Fatma Ben Salem"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7434",title:"Molecular Biotechnology",subtitle:null,isOpenForSubmission:!1,hash:"eceede809920e1ec7ecadd4691ede2ec",slug:"molecular-biotechnology",bookSignature:"Sergey Sedykh",coverURL:"https://cdn.intechopen.com/books/images_new/7434.jpg",editors:[{id:"178316",title:"Ph.D.",name:"Sergey",middleName:null,surname:"Sedykh",slug:"sergey-sedykh",fullName:"Sergey Sedykh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9839",title:"Outdoor Recreation",subtitle:"Physiological and Psychological Effects on Health",isOpenForSubmission:!1,hash:"5f5a0d64267e32567daffa5b0c6a6972",slug:"outdoor-recreation-physiological-and-psychological-effects-on-health",bookSignature:"Hilde G. Nielsen",coverURL:"https://cdn.intechopen.com/books/images_new/9839.jpg",editors:[{id:"158692",title:"Ph.D.",name:"Hilde G.",middleName:null,surname:"Nielsen",slug:"hilde-g.-nielsen",fullName:"Hilde G. Nielsen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9208",title:"Welding",subtitle:"Modern Topics",isOpenForSubmission:!1,hash:"7d6be076ccf3a3f8bd2ca52d86d4506b",slug:"welding-modern-topics",bookSignature:"Sadek Crisóstomo Absi Alfaro, Wojciech Borek and Błażej Tomiczek",coverURL:"https://cdn.intechopen.com/books/images_new/9208.jpg",editors:[{id:"65292",title:"Prof.",name:"Sadek Crisostomo Absi",middleName:"C. Absi",surname:"Alfaro",slug:"sadek-crisostomo-absi-alfaro",fullName:"Sadek Crisostomo Absi Alfaro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9343",title:"Trace Metals in the Environment",subtitle:"New Approaches and Recent Advances",isOpenForSubmission:!1,hash:"ae07e345bc2ce1ebbda9f70c5cd12141",slug:"trace-metals-in-the-environment-new-approaches-and-recent-advances",bookSignature:"Mario Alfonso Murillo-Tovar, Hugo Saldarriaga-Noreña and Agnieszka Saeid",coverURL:"https://cdn.intechopen.com/books/images_new/9343.jpg",editors:[{id:"255959",title:"Dr.",name:"Mario Alfonso",middleName:null,surname:"Murillo-Tovar",slug:"mario-alfonso-murillo-tovar",fullName:"Mario Alfonso Murillo-Tovar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8697",title:"Virtual Reality and Its Application in Education",subtitle:null,isOpenForSubmission:!1,hash:"ee01b5e387ba0062c6b0d1e9227bda05",slug:"virtual-reality-and-its-application-in-education",bookSignature:"Dragan Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/8697.jpg",editors:[{id:"101330",title:"Dr.",name:"Dragan",middleName:"Mladen",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7831",title:"Sustainability in Urban Planning and Design",subtitle:null,isOpenForSubmission:!1,hash:"c924420492c8c2c9751e178d025f4066",slug:"sustainability-in-urban-planning-and-design",bookSignature:"Amjad Almusaed, Asaad Almssad and Linh Truong - Hong",coverURL:"https://cdn.intechopen.com/books/images_new/7831.jpg",editors:[{id:"110471",title:"Dr.",name:"Amjad",middleName:"Zaki",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5138},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"9208",title:"Welding",subtitle:"Modern Topics",isOpenForSubmission:!1,hash:"7d6be076ccf3a3f8bd2ca52d86d4506b",slug:"welding-modern-topics",bookSignature:"Sadek Crisóstomo Absi Alfaro, Wojciech Borek and Błażej Tomiczek",coverURL:"https://cdn.intechopen.com/books/images_new/9208.jpg",editors:[{id:"65292",title:"Prof.",name:"Sadek Crisostomo Absi",middleName:"C. Absi",surname:"Alfaro",slug:"sadek-crisostomo-absi-alfaro",fullName:"Sadek Crisostomo Absi Alfaro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8697",title:"Virtual Reality and Its Application in Education",subtitle:null,isOpenForSubmission:!1,hash:"ee01b5e387ba0062c6b0d1e9227bda05",slug:"virtual-reality-and-its-application-in-education",bookSignature:"Dragan Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/8697.jpg",editors:[{id:"101330",title:"Dr.",name:"Dragan",middleName:"Mladen",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9343",title:"Trace Metals in the Environment",subtitle:"New Approaches and Recent Advances",isOpenForSubmission:!1,hash:"ae07e345bc2ce1ebbda9f70c5cd12141",slug:"trace-metals-in-the-environment-new-approaches-and-recent-advances",bookSignature:"Mario Alfonso Murillo-Tovar, Hugo Saldarriaga-Noreña and Agnieszka Saeid",coverURL:"https://cdn.intechopen.com/books/images_new/9343.jpg",editors:[{id:"255959",title:"Dr.",name:"Mario Alfonso",middleName:null,surname:"Murillo-Tovar",slug:"mario-alfonso-murillo-tovar",fullName:"Mario Alfonso Murillo-Tovar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9785",title:"Endometriosis",subtitle:null,isOpenForSubmission:!1,hash:"f457ca61f29cf7e8bc191732c50bb0ce",slug:"endometriosis",bookSignature:"Courtney Marsh",coverURL:"https://cdn.intechopen.com/books/images_new/9785.jpg",editors:[{id:"255491",title:"Dr.",name:"Courtney",middleName:null,surname:"Marsh",slug:"courtney-marsh",fullName:"Courtney Marsh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7831",title:"Sustainability in Urban Planning and Design",subtitle:null,isOpenForSubmission:!1,hash:"c924420492c8c2c9751e178d025f4066",slug:"sustainability-in-urban-planning-and-design",bookSignature:"Amjad Almusaed, Asaad Almssad and Linh Truong - Hong",coverURL:"https://cdn.intechopen.com/books/images_new/7831.jpg",editors:[{id:"110471",title:"Dr.",name:"Amjad",middleName:"Zaki",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9376",title:"Contemporary Developments and Perspectives in International Health Security",subtitle:"Volume 1",isOpenForSubmission:!1,hash:"b9a00b84cd04aae458fb1d6c65795601",slug:"contemporary-developments-and-perspectives-in-international-health-security-volume-1",bookSignature:"Stanislaw P. Stawicki, Michael S. Firstenberg, Sagar C. Galwankar, Ricardo Izurieta and Thomas Papadimos",coverURL:"https://cdn.intechopen.com/books/images_new/9376.jpg",editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7769",title:"Medical Isotopes",subtitle:null,isOpenForSubmission:!1,hash:"f8d3c5a6c9a42398e56b4e82264753f7",slug:"medical-isotopes",bookSignature:"Syed Ali Raza Naqvi and Muhammad Babar Imrani",coverURL:"https://cdn.intechopen.com/books/images_new/7769.jpg",editors:[{id:"259190",title:"Dr.",name:"Syed Ali Raza",middleName:null,surname:"Naqvi",slug:"syed-ali-raza-naqvi",fullName:"Syed Ali Raza Naqvi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9279",title:"Concepts, Applications and Emerging Opportunities in Industrial Engineering",subtitle:null,isOpenForSubmission:!1,hash:"9bfa87f9b627a5468b7c1e30b0eea07a",slug:"concepts-applications-and-emerging-opportunities-in-industrial-engineering",bookSignature:"Gary Moynihan",coverURL:"https://cdn.intechopen.com/books/images_new/9279.jpg",editors:[{id:"16974",title:"Dr.",name:"Gary",middleName:null,surname:"Moynihan",slug:"gary-moynihan",fullName:"Gary Moynihan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7807",title:"A Closer Look at Organizational Culture in Action",subtitle:null,isOpenForSubmission:!1,hash:"05c608b9271cc2bc711f4b28748b247b",slug:"a-closer-look-at-organizational-culture-in-action",bookSignature:"Süleyman Davut Göker",coverURL:"https://cdn.intechopen.com/books/images_new/7807.jpg",editors:[{id:"190035",title:"Associate Prof.",name:"Süleyman Davut",middleName:null,surname:"Göker",slug:"suleyman-davut-goker",fullName:"Süleyman Davut Göker"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"7434",title:"Molecular Biotechnology",subtitle:null,isOpenForSubmission:!1,hash:"eceede809920e1ec7ecadd4691ede2ec",slug:"molecular-biotechnology",bookSignature:"Sergey Sedykh",coverURL:"https://cdn.intechopen.com/books/images_new/7434.jpg",editedByType:"Edited by",editors:[{id:"178316",title:"Ph.D.",name:"Sergey",middleName:null,surname:"Sedykh",slug:"sergey-sedykh",fullName:"Sergey Sedykh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8545",title:"Animal Reproduction in Veterinary Medicine",subtitle:null,isOpenForSubmission:!1,hash:"13aaddf5fdbbc78387e77a7da2388bf6",slug:"animal-reproduction-in-veterinary-medicine",bookSignature:"Faruk Aral, Rita Payan-Carreira and Miguel Quaresma",coverURL:"https://cdn.intechopen.com/books/images_new/8545.jpg",editedByType:"Edited by",editors:[{id:"25600",title:"Prof.",name:"Faruk",middleName:null,surname:"Aral",slug:"faruk-aral",fullName:"Faruk Aral"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9569",title:"Methods in Molecular Medicine",subtitle:null,isOpenForSubmission:!1,hash:"691d3f3c4ac25a8093414e9b270d2843",slug:"methods-in-molecular-medicine",bookSignature:"Yusuf Tutar",coverURL:"https://cdn.intechopen.com/books/images_new/9569.jpg",editedByType:"Edited by",editors:[{id:"158492",title:"Prof.",name:"Yusuf",middleName:null,surname:"Tutar",slug:"yusuf-tutar",fullName:"Yusuf Tutar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9839",title:"Outdoor Recreation",subtitle:"Physiological and Psychological Effects on Health",isOpenForSubmission:!1,hash:"5f5a0d64267e32567daffa5b0c6a6972",slug:"outdoor-recreation-physiological-and-psychological-effects-on-health",bookSignature:"Hilde G. Nielsen",coverURL:"https://cdn.intechopen.com/books/images_new/9839.jpg",editedByType:"Edited by",editors:[{id:"158692",title:"Ph.D.",name:"Hilde G.",middleName:null,surname:"Nielsen",slug:"hilde-g.-nielsen",fullName:"Hilde G. Nielsen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7802",title:"Modern Slavery and Human Trafficking",subtitle:null,isOpenForSubmission:!1,hash:"587a0b7fb765f31cc98de33c6c07c2e0",slug:"modern-slavery-and-human-trafficking",bookSignature:"Jane Reeves",coverURL:"https://cdn.intechopen.com/books/images_new/7802.jpg",editedByType:"Edited by",editors:[{id:"211328",title:"Prof.",name:"Jane",middleName:null,surname:"Reeves",slug:"jane-reeves",fullName:"Jane Reeves"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8063",title:"Food Security in Africa",subtitle:null,isOpenForSubmission:!1,hash:"8cbf3d662b104d19db2efc9d59249efc",slug:"food-security-in-africa",bookSignature:"Barakat Mahmoud",coverURL:"https://cdn.intechopen.com/books/images_new/8063.jpg",editedByType:"Edited by",editors:[{id:"92016",title:"Dr.",name:"Barakat",middleName:null,surname:"Mahmoud",slug:"barakat-mahmoud",fullName:"Barakat Mahmoud"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10118",title:"Plant Stress Physiology",subtitle:null,isOpenForSubmission:!1,hash:"c68b09d2d2634fc719ae3b9a64a27839",slug:"plant-stress-physiology",bookSignature:"Akbar Hossain",coverURL:"https://cdn.intechopen.com/books/images_new/10118.jpg",editedByType:"Edited by",editors:[{id:"280755",title:"Dr.",name:"Akbar",middleName:null,surname:"Hossain",slug:"akbar-hossain",fullName:"Akbar Hossain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9157",title:"Neurodegenerative Diseases",subtitle:"Molecular Mechanisms and Current Therapeutic Approaches",isOpenForSubmission:!1,hash:"bc8be577966ef88735677d7e1e92ed28",slug:"neurodegenerative-diseases-molecular-mechanisms-and-current-therapeutic-approaches",bookSignature:"Nagehan Ersoy Tunalı",coverURL:"https://cdn.intechopen.com/books/images_new/9157.jpg",editedByType:"Edited by",editors:[{id:"82778",title:"Ph.D.",name:"Nagehan",middleName:null,surname:"Ersoy Tunalı",slug:"nagehan-ersoy-tunali",fullName:"Nagehan Ersoy Tunalı"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9961",title:"Data Mining",subtitle:"Methods, Applications and Systems",isOpenForSubmission:!1,hash:"ed79fb6364f2caf464079f94a0387146",slug:"data-mining-methods-applications-and-systems",bookSignature:"Derya Birant",coverURL:"https://cdn.intechopen.com/books/images_new/9961.jpg",editedByType:"Edited by",editors:[{id:"15609",title:"Dr.",name:"Derya",middleName:null,surname:"Birant",slug:"derya-birant",fullName:"Derya Birant"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8686",title:"Direct Torque Control Strategies of Electrical Machines",subtitle:null,isOpenForSubmission:!1,hash:"b6ad22b14db2b8450228545d3d4f6b1a",slug:"direct-torque-control-strategies-of-electrical-machines",bookSignature:"Fatma Ben Salem",coverURL:"https://cdn.intechopen.com/books/images_new/8686.jpg",editedByType:"Edited by",editors:[{id:"295623",title:"Associate Prof.",name:"Fatma",middleName:null,surname:"Ben Salem",slug:"fatma-ben-salem",fullName:"Fatma Ben Salem"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"1118",title:"Clinical Electrophysiology",slug:"clinical-electrophysiology",parent:{title:"Physical Medicine and Rehabilitation",slug:"physical-medicine-and-rehabilitation"},numberOfBooks:1,numberOfAuthorsAndEditors:20,numberOfWosCitations:1,numberOfCrossrefCitations:6,numberOfDimensionsCitations:9,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"clinical-electrophysiology",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"5782",title:"Clinical Physical Therapy",subtitle:null,isOpenForSubmission:!1,hash:"4fb576229359708e5e14d59b1083fdc1",slug:"clinical-physical-therapy",bookSignature:"Toshiaki Suzuki",coverURL:"https://cdn.intechopen.com/books/images_new/5782.jpg",editedByType:"Edited by",editors:[{id:"70872",title:"Prof.",name:"Toshiaki",middleName:null,surname:"Suzuki",slug:"toshiaki-suzuki",fullName:"Toshiaki Suzuki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:1,mostCitedChapters:[{id:"54472",doi:"10.5772/67595",title:"Physiotherapy and Mental Health",slug:"physiotherapy-and-mental-health",totalDownloads:7379,totalCrossrefCites:2,totalDimensionsCites:4,book:{slug:"clinical-physical-therapy",title:"Clinical Physical Therapy",fullTitle:"Clinical Physical Therapy"},signatures:"Michel Probst",authors:[{id:"186905",title:"Prof.",name:"Michel",middleName:null,surname:"Probst",slug:"michel-probst",fullName:"Michel Probst"}]},{id:"54692",doi:"10.5772/67528",title:"Comprehensive Physical Function Assessment in Elderly People",slug:"comprehensive-physical-function-assessment-in-elderly-people",totalDownloads:1098,totalCrossrefCites:2,totalDimensionsCites:2,book:{slug:"clinical-physical-therapy",title:"Clinical Physical Therapy",fullTitle:"Clinical Physical Therapy"},signatures:"Tadashi Ito",authors:[{id:"196581",title:"Ph.D.",name:"Tadashi",middleName:null,surname:"Ito",slug:"tadashi-ito",fullName:"Tadashi Ito"}]},{id:"54480",doi:"10.5772/67752",title:"Conservative Management of Chronic Venous Insufficiency",slug:"conservative-management-of-chronic-venous-insufficiency",totalDownloads:1461,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"clinical-physical-therapy",title:"Clinical Physical Therapy",fullTitle:"Clinical Physical Therapy"},signatures:"Özlem Çinar Özdemir and Mahmut Surmeli",authors:[{id:"185712",title:"Ph.D.",name:"Özlem",middleName:null,surname:"Çinar Özdemir",slug:"ozlem-cinar-ozdemir",fullName:"Özlem Çinar Özdemir"},{id:"193852",title:"Mr.",name:"Mahmut",middleName:null,surname:"Surmeli",slug:"mahmut-surmeli",fullName:"Mahmut Surmeli"}]}],mostDownloadedChaptersLast30Days:[{id:"53866",title:"Physical Therapy in Patients with Cancer",slug:"physical-therapy-in-patients-with-cancer",totalDownloads:2824,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"clinical-physical-therapy",title:"Clinical Physical Therapy",fullTitle:"Clinical Physical Therapy"},signatures:"Shinichiro Morishita and Atsuhiro Tsubaki",authors:[{id:"139514",title:"Ph.D.",name:"Shinichiro",middleName:null,surname:"Morishita",slug:"shinichiro-morishita",fullName:"Shinichiro Morishita"},{id:"202889",title:"Dr.",name:"Atsuhiro",middleName:null,surname:"Tsubaki",slug:"atsuhiro-tsubaki",fullName:"Atsuhiro Tsubaki"}]},{id:"54472",title:"Physiotherapy and Mental Health",slug:"physiotherapy-and-mental-health",totalDownloads:7379,totalCrossrefCites:2,totalDimensionsCites:4,book:{slug:"clinical-physical-therapy",title:"Clinical Physical Therapy",fullTitle:"Clinical Physical Therapy"},signatures:"Michel Probst",authors:[{id:"186905",title:"Prof.",name:"Michel",middleName:null,surname:"Probst",slug:"michel-probst",fullName:"Michel Probst"}]},{id:"55065",title:"Exercise Therapy for Physical Therapist",slug:"exercise-therapy-for-physical-therapist",totalDownloads:1545,totalCrossrefCites:0,totalDimensionsCites:1,book:{slug:"clinical-physical-therapy",title:"Clinical Physical Therapy",fullTitle:"Clinical Physical Therapy"},signatures:"Naruemon Leelayuwat",authors:[{id:"196387",title:"Associate Prof.",name:"Naruemon",middleName:null,surname:"Leelayuwat",slug:"naruemon-leelayuwat",fullName:"Naruemon Leelayuwat"}]},{id:"54480",title:"Conservative Management of Chronic Venous Insufficiency",slug:"conservative-management-of-chronic-venous-insufficiency",totalDownloads:1461,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"clinical-physical-therapy",title:"Clinical Physical Therapy",fullTitle:"Clinical Physical Therapy"},signatures:"Özlem Çinar Özdemir and Mahmut Surmeli",authors:[{id:"185712",title:"Ph.D.",name:"Özlem",middleName:null,surname:"Çinar Özdemir",slug:"ozlem-cinar-ozdemir",fullName:"Özlem Çinar Özdemir"},{id:"193852",title:"Mr.",name:"Mahmut",middleName:null,surname:"Surmeli",slug:"mahmut-surmeli",fullName:"Mahmut Surmeli"}]},{id:"54689",title:"Pelvic Movement in Aging Individuals and Stroke Patients",slug:"pelvic-movement-in-aging-individuals-and-stroke-patients",totalDownloads:921,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"clinical-physical-therapy",title:"Clinical Physical Therapy",fullTitle:"Clinical Physical Therapy"},signatures:"Hitoshi Asai",authors:[{id:"198129",title:"Prof.",name:"Hitoshi",middleName:null,surname:"Asai",slug:"hitoshi-asai",fullName:"Hitoshi Asai"}]},{id:"55041",title:"Manual Lymphatic Drainage in the Treatment of Chronic Venous Disease",slug:"manual-lymphatic-drainage-in-the-treatment-of-chronic-venous-disease",totalDownloads:1291,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"clinical-physical-therapy",title:"Clinical Physical Therapy",fullTitle:"Clinical Physical Therapy"},signatures:"Rute S.S. Crisóstomo and Paulo A.S. Armada-da-Silva",authors:[{id:"197861",title:"Ph.D.",name:"Rute",middleName:null,surname:"Crisóstomo",slug:"rute-crisostomo",fullName:"Rute Crisóstomo"},{id:"205140",title:"Prof.",name:"Paulo A. S.",middleName:null,surname:"Armada-Da-Silva",slug:"paulo-a.-s.-armada-da-silva",fullName:"Paulo A. S. Armada-Da-Silva"}]},{id:"54608",title:"Special Rehabilitation Treatment Methodology: INFINITY method®",slug:"special-rehabilitation-treatment-methodology-infinity-method-",totalDownloads:814,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"clinical-physical-therapy",title:"Clinical Physical Therapy",fullTitle:"Clinical Physical Therapy"},signatures:"Michaela Tomanova",authors:[{id:"198202",title:"Ph.D.",name:"Michaela",middleName:null,surname:"Tomanova",slug:"michaela-tomanova",fullName:"Michaela Tomanova"}]},{id:"54178",title:"Influence of Auditory Pacing on the Control of Rhythmic Movement in Physical Therapy",slug:"influence-of-auditory-pacing-on-the-control-of-rhythmic-movement-in-physical-therapy",totalDownloads:914,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"clinical-physical-therapy",title:"Clinical Physical Therapy",fullTitle:"Clinical Physical Therapy"},signatures:"Masanori Ito, Yuki Takahashi, Satoshi Fujiwara and Naoki Kado",authors:[{id:"197850",title:"Dr.",name:"Masanori",middleName:null,surname:"Ito",slug:"masanori-ito",fullName:"Masanori Ito"},{id:"198091",title:"Dr.",name:"Naoki",middleName:null,surname:"Kado",slug:"naoki-kado",fullName:"Naoki Kado"},{id:"204588",title:"MSc.",name:"Yuki",middleName:null,surname:"Takahashi",slug:"yuki-takahashi",fullName:"Yuki Takahashi"},{id:"204589",title:"MSc.",name:"Satoshi",middleName:null,surname:"Fujiwara",slug:"satoshi-fujiwara",fullName:"Satoshi Fujiwara"}]},{id:"54293",title:"The Function of Scapular Muscle",slug:"the-function-of-scapular-muscle",totalDownloads:1466,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"clinical-physical-therapy",title:"Clinical Physical Therapy",fullTitle:"Clinical Physical Therapy"},signatures:"Tomohito Ijiri",authors:[{id:"197891",title:"M.Sc.",name:"Tomohito",middleName:null,surname:"Ijiri",slug:"tomohito-ijiri",fullName:"Tomohito Ijiri"}]},{id:"54692",title:"Comprehensive Physical Function Assessment in Elderly People",slug:"comprehensive-physical-function-assessment-in-elderly-people",totalDownloads:1098,totalCrossrefCites:2,totalDimensionsCites:2,book:{slug:"clinical-physical-therapy",title:"Clinical Physical Therapy",fullTitle:"Clinical Physical Therapy"},signatures:"Tadashi Ito",authors:[{id:"196581",title:"Ph.D.",name:"Tadashi",middleName:null,surname:"Ito",slug:"tadashi-ito",fullName:"Tadashi Ito"}]}],onlineFirstChaptersFilter:{topicSlug:"clinical-electrophysiology",limit:3,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/189561/mihaela-laura-vica",hash:"",query:{},params:{id:"189561",slug:"mihaela-laura-vica"},fullPath:"/profiles/189561/mihaela-laura-vica",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()